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unique challenges for achieving reimbursement and market access. In the 
current study, we identified key issues influencing imaging diagnostics 
reimbursement and market access through a review of global health technology 
assessments (HTAs). METHODS: We identified and reviewed global imaging 
diagnostics HTAs for criteria scrutinized and concerns registered by the issuing 
agencies. Technologies reviewed in HTAs included computed tomography (CT), 
ultrasound, positron emission tomography (PET), single photon emission CT 
(SPECT), magnetic resonance imaging (MRI), laser scanning, thermography and 
standard camera-based methods. Diagnostic applications were relevant to 
oncology, gastroenterology, cardiovascular, degenerative, injury/infection, and 
neurological disease indications. RESULTS: For imaging diagnostic applications, 
HTA agencies scrutinized a variety of criteria fitting categories of evidence 
relevant to all diagnostic testing. These categories included Clinical 
Validity/Utility, Economic Value/Cost, Testing Logistics, and Safety/Ethical 
Considerations. Scrutinized criteria that were unique to imaging diagnostic 
applications mainly pertained to the Testing Logistics and Safety/Ethical 
Considerations categories of evidence, such as impact of adding new diagnostic 
applications on patient wait times for existing imaging procedures (especially for 
applications using platforms with already burdened queues), safety of imaging 
diagnostics-associated radiopharmaceuticals and contrast agents, and radiation 
dose/potential health impact of exposure. CONCLUSIONS: Imaging diagnostics 
hold the potential to improve health outcomes and reduce health care costs 
through earlier disease detection and avoidance of more invasive methods. To 
increase the likelihood of favorable reimbursement and market access for novel 
imaging diagnostic applications, evidence to support HTA review should be 
considered and planned for early in product development.  
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OBJECTIVES: There is growing concern about the unsustainable rise in health 
care costs and whether such spending levels are commensurate with better 
quality of care and improved health outcomes. Consequently, policy makers are 
aiming to attain greater value from new technologies. This study sought to 
examine existing reimbursement and pricing policies for medical devices in 
Europe and the US, identify key challenges in defining and assessing their value, 
and explore various policy options to obtain greater value from these 
technologies. METHODS: The study examined the respective reimbursement and 
pricing systems for medical devices based on a critical review of available, 
relevant scientific and grey literature. In addition, the websites of national 
payers (e.g., CMS) and HTA bodies (e.g., NICE) were reviewed for key policy 
documents. RESULTS: Current reimbursement and pricing systems for medical 
devices in both Europe and the US raise a number of issues: 1) the majority of 
countries apply the same assessment and reimbursement and pricing 
frameworks to all technologies; 2) most funding decisions in the US are made at 
the local level, where policies and evidence standards can vary across 
states/payers; 3) where evidence of value is used in decision making, notably in 
Europe, it is generally better linked to coverage determinations, as opposed to 
identifying appropriate reimbursement prices; and 4) a number of 
methodological challenges exist for measuring the value of devices, including 
generating evidence of effectiveness via RCTs, accounting for the ‘learning curve’ 
of clinicians as well as the complex impact of medical devices on health 
systems, and capturing some of the benefits afforded by medical devices (e.g., 
increased patient convenience). CONCLUSIONS: New policies focused on 
improving the clinical and economic base on devices, developing new 
approaches to assess their value, and strengthening the link between 
reimbursement and evidence of value are needed.  
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OBJECTIVES: To describe and evaluate theoretical frameworks and practical 
examples to harmonize processes and evidentiary requirements in health 
technology assessment (HTA) and regulatory approval. METHODS: A systematic 
review was conducted to identify relevant scholarly work and policy documents 
relating to harmonization or alignment of HTA and regulatory processes. 
Bibliographies were screened by two independent reviewers and websites were 
evaluated to identify additional relevant documents. To supplement the literature 
search, semi-structured interviews were conducted with key international 
stakeholders from a broad range of perspectives including HTA, regulators, 
academics and payers. RESULTS: A considerable degree of overlap exists between 
HTA and regulatory approval, and harmonization of certain aspects is possible. 
Various theoretical models have been put forth and there have been a number of 
practical attempts reported that have drawn to varying degrees on these theories. 
Based on the international review, approaches to harmonize can be categorized into 
those: 1) focused on reducing uncertainty in the evidentiary requirements (e.g. early 
dialogue, alignment of evidentiary requirements); 2) focused on aligning the 
timeframe and other logistical aspects in the review process (e.g. adaptive licensing, 
parallel licensing); or 3) a mix of the above two (e.g. pre-market trial development). 
These strategies can further be classified on a spectrum based on their expected level 
of structural and organizational change required to implement them into the existing 
regulatory-HTA processes. Passive processes require less radical structural and 
operational changes while active processes require greater restructuring. 
CONCLUSIONS: Harmonization of regulatory and HTA processes may be feasible for 
both pharmaceutical and non-pharmaceutical health technologies. Greater 
harmonization benefits patients, manufacturers and all levels of the health care 
system. However, attempts at harmonization so far have raised numerous legal, 
political and practical issues. These challenges must be considered when introducing 
a harmonized framework into the existing regulatory and HTA framework.  
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OBJECTIVES: To examine factors associated with online pharmacy use in a 
nationally representative sample. METHODS: Data were from the 2002-2009 
Medical Expenditure Panel Survey. Individuals who participated in the survey for 
two years and had ≥1 prescriptions were included. Online pharmacy use was 
assessed by “pharmacy type” variables for medications reported in prescription 
data files. Univariate analyses of online use were performed with 
sociodemographic information, medications classes, disease states, Charlson 
Comorbidity Index (CCI), prescription insurance coverage, and health care 
expenditures and utilization. Significant variables and variables that have been 
shown to be associated with internet use for health information were further 
adjusted in a multivariate logistic regression model predicting online pharmacy 
use. STATA survey commends were used to account for complex survey design. 
RESULTS: A total of 449 online users were identified across 8 panels of MEPS 
representing a weighted prevalence of 0.66% and population estimate of nearly 
1.5 million. After adjusting for sociodemographic differences, higher nondrug 
health care expenditures (log-transformed) [OR=1.09 (1.01-1.18)], prescription 
expenditures (log-transformed) [OR=1.25 (1.14-1.37)], having five or more 
prescriptions [OR=5.19 (1.639-16.43)], and use of erectile dysfunction medications 
[OR=2.28 (1.06-4.90)] were associated with more online pharmacy use. Black race 
[OR=0.48 (0.31-0.74)] and Medicaid coverage [OR=0.29 (0.17-0.52)] were inversely 
related to online pharmacy use. Among common “internet drugs of abuse”; 
including stimulants, sedatives, and narcotic medications, only narcotic 
medications were associated with online pharmacy use [OR=0.67 (0.50-0.90)] in 
the multivariate regression analysis. CONCLUSIONS: Using nationally 
representative data, this study showed that age, race, insurance coverage, health 
care expenditures and number of prescriptions are predictors for online 
pharmacy use.  
 
PHP33  
KENTUCKY PHYSICIAN OPINIONS OF THE POTENTIAL RECLASSIFICATION OF 
PSEUDOEPHEDRINE AS A LEGEND DRUG  
Goodin AJ, Freeman PR, Talbert J, Monson K, Blumenschein K 
University of Kentucky, Lexington, KY, USA  
OBJECTIVES: Pseudoephedrine (PSE) is used as a precursor in the illicit 
production of methamphetamine. Several policies have been adopted to control 
access to PSE, including tracking of sales, quantity restrictions and, in two states, 
the reclassification of PSE as a Schedule III controlled substance. In 2012, the 
Kentucky Legislature considered a controversial bill proposing the 
reclassification of PSE as a legend drug available by prescription only. The 
purpose of this study is to assess physician opinion of the proposed legislation. 
METHODS: A simple random sample of 2000 licensed physicians in Kentucky 
were mailed a survey that solicited opinions on the proposed PSE legislation. 
Non-responders were contacted via reminder postcards twice between June and 
July of 2012 and were offered the option to complete a survey electronically. 
Response frequencies were calculated and logistic regression was used to 
analyze the impact of physician characteristics such as confidence in the ability 
to identify legitimate PSE use, practice type, urbanicity, legislation awareness, 
and estimated frequency of PSE demand on likelihood of PSE legislation support. 
RESULTS: Excluding bad addresses, 243 surveys were returned (response 
rate=12.5%). Physician support for legislation to reclassify PSE as a legend drug 
was mixed, with 41.3% in support, 40.5% in opposition and 18.2% unsure. 
Physicians supporting the legislation most commonly cited reduced risk of 
methamphetamine abuse (55.5%) as reason for support. Physicians who reported 
being confident in their ability to identify legitimate PSE use were more likely to 
express support (p=0.026), as were those reporting low estimated requests for 
PSE during peak allergy/flu season (p=0.002). Physicians in urban counties were 
less likely to express support (p<0.001). CONCLUSIONS: These findings suggest 
that Kentucky physicians are divided on the issue of PSE reclassification and that 
physician characteristics influence opinion. The potential impact on physician 
behavior should be considered when evaluating PSE policy options.  
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OBJECTIVES: Mechanism of action (MOA) is the description of a biochemical 
event, usually indicative of the drug’s pharmacological activity. The U.S. Food 
and Drug Administration (FDA) requires MOA to be described on the drug’s label. 
The MOA is important because it assists health providers in understanding the 
therapeutic applications and possible adverse reactions of a drug. This study 
assessed the MOA of new drugs and biologics approved by the FDA between 1980 
and 2011. METHODS: Information was collected from drug labels available online 
